Natural killer (NK) cells are immune cells, and exercise studies can measure them in very different ways. A blood sample can report NK cells as a percentage of lymphocytes (white blood cells) or as an absolute count in cells/µL at one moment. A tumour study asks whether NK cells are present inside tumour tissue. Those measurements are not interchangeable. A rise in a blood sample is not evidence that the same cells have entered a tumour, nor that a patient will do better.
A concrete example is a 30-participant randomised controlled trial in men with localised prostate cancer. The trial tested exercise training for increasing tumour NK-cell infiltration. Its intention-to-treat analysis found no significant between-group difference in tumour NK-cell infiltration. That is a result about tumour tissue, not a blood count after a workout.
Acute blood changes are a snapshot
Mayo Clinic Laboratories reports a quantitative lymphocyte subset test for blood that includes relative percentages, absolute counts and a T/B/NK classification. The relative percentage is the share of lymphocytes that are NK cells. The absolute count is how many NK cells are present per microlitre. Both come from the sample in front of the lab, so they describe the circulation at that moment. The same organisation notes that its reference intervals are for that laboratory; they should not be applied to another laboratory's report.
Acute means short-term—around a single session or a brief training period. A short-term blood change can answer a question about circulating immune cells. It cannot, by itself, show tumour infiltration or a clinical benefit.
Tumour infiltration is a different endpoint
The prostate cancer trial measured tumour NK-cell infiltration: whether NK cells were present in tumour tissue and in what amount. That requires tumour tissue, not a blood sample. In the trial's intention-to-treat analysis, the between-group difference in tumour NK-cell infiltration was not significant. Intention-to-treat means participants were analysed by the group they were assigned to, not only by who completed the programme. A between-group difference is the comparison between the exercise group and the comparator group. Not significant means this trial's primary analysis did not find a statistically significant difference between groups; it is not a claim that no effect could exist in any setting.
The result should not be rewritten as 'exercise raises anti-cancer NK activity.' In this trial, the reported primary comparison on tumour NK-cell infiltration was not significant.
The clock matters: blood now, tissue later, outcomes later still
Short-term blood measurements and long-term tumour outcomes sit on different clocks. A blood count describes cells in circulation around the time of sampling. Tumour infiltration describes cells in tissue. A clinical outcome describes what happens to a person over time, such as whether cancer progresses or whether they survive. A cell count is not a clinical outcome, and a laboratory assay showing that NK cells can kill target cells in a dish is not a patient benefit. The prostate trial result concerns tumour NK-cell infiltration; it should not be converted into a survival claim or a general anti-cancer claim.
Swipe or scroll to read the full table →
| What is measured | Sample | What it can show | What it cannot show on its own |
|---|---|---|---|
| NK cells as a relative percentage | Blood | NK cells' share of lymphocytes in that sample | The absolute number of NK cells, tumour infiltration or clinical benefit |
| NK cells as an absolute count | Blood | NK cells per microlitre in that sample | Whether those cells are active in tumour tissue or improving a patient outcome |
| Tumour NK-cell infiltration | Tumour tissue | Whether NK cells are present in tumour tissue and in what amount, as measured in the trial | A blood count or a long-term clinical outcome |
How to read an NK-cell claim
Start with the sample. Blood or tumour tissue? A blood sample cannot directly show tumour infiltration.
Check the unit. A relative percentage and an absolute count answer different questions. Mayo Clinic Laboratories reports both for its blood lymphocyte subset test.
Check the lab range. Mayo notes its reference intervals belong to that laboratory and should not be applied elsewhere.
Check the endpoint. Is the study reporting a short-term blood measurement, a tumour tissue measurement, a laboratory killing assay, or a clinical event? These are different levels of evidence.
Keep the wording honest. 'NK cells increased in blood after exercise' is not the same as 'exercise increased NK cells in tumours' or 'exercise improved cancer outcomes.'
What the prostate trial does and does not establish
The 30-participant randomised trial in localised prostate cancer is relevant to the exercise and natural killer cells question because its reported endpoint was tumour tissue, not a blood count. Its primary intention-to-treat comparison on tumour NK-cell infiltration was not significant. That makes it a caution against turning an exercise-related immune change into a cancer-benefit claim. It does not tell us that exercise has no health effects, and it does not establish a long-term cancer outcome from NK-cell infiltration. Those are separate questions.
This is general educational information, not medical advice. Laboratory results are interpreted with the testing laboratory's own reference interval and the person's full clinical context.